| Coagulation and cancer: biological and clinical aspects A Falanga, M Marchetti, A Vignoli Journal of Thrombosis and Haemostasis 11 (2), 223-233, 2013 | 556 | 2013 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 546 | 2020 |
| Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet T Barbui, A Tefferi, AM Vannucchi, F Passamonti, RT Silver, R Hoffman, ... Leukemia 32 (5), 1057-1069, 2018 | 545 | 2018 |
| Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European … O Penack, M Marchetti, T Ruutu, M Aljurf, A Bacigalupo, F Bonifazi, ... The Lancet Haematology 7 (2), e157-e167, 2020 | 430 | 2020 |
| Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the … T Barbui, G Barosi, A Grossi, L Gugliotta, LN Liberato, M Marchetti, ... haematologica 89 (2), 215-232, 2004 | 392 | 2004 |
| JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis G Barosi, G Bergamaschi, M Marchetti, AM Vannucchi, P Guglielmelli, ... Blood, The Journal of the American Society of Hematology 110 (12), 4030-4036, 2007 | 300 | 2007 |
| Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia G Barosi, G Viarengo, A Pecci, V Rosti, G Piaggio, M Marchetti, F Frassoni Blood, The Journal of the American Society of Hematology 98 (12), 3249-3255, 2001 | 276 | 2001 |
| Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders E Angelucci, G Barosi, C Camaschella, MD Cappellini, M Cazzola, ... haematologica 93 (5), 741-752, 2008 | 265 | 2008 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 260 | 2020 |
| COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) L Pagano, J Salmanton-García, F Marchesi, A Busca, P Corradini, ... Journal of hematology & oncology 14 (1), 168, 2021 | 250 | 2021 |
| A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts M Bassetti, M Marchetti, A Chakrabarti, S Colizza, J Garnacho-Montero, ... Intensive care medicine 39, 2092-2106, 2013 | 223 | 2013 |
| Proposed definition of ‘poor mobilizer’in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo A Olivieri, M Marchetti, R Lemoli, C Tarella, A Iacone, F Lanza, ... Bone marrow transplantation 47 (3), 342-351, 2012 | 219 | 2012 |
| Chronic myeloproliferative disorders JL Spivak, G Barosi, G Tognoni, T Barbui, G Finazzi, R Marchioli, ... ASH Education Program Book 2003 (1), 200-224, 2003 | 209 | 2003 |
| Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial M Marchetti, G Barosi, F Balestri, G Viarengo, S Gentili, S Barulli, ... Journal of clinical oncology 22 (3), 424-431, 2004 | 187 | 2004 |
| Consensus conference on the management of tumor lysis syndrome. P Tosi, G Barosi, C Lazzaro, V Liso, M Marchetti, E Morra, A Pession, ... haematologica 93, 1877-1885, 2008 | 179 | 2008 |
| Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2–positive breast cancer NL Liberato, M Marchetti, G Barosi Journal of Clinical Oncology 25 (6), 625-633, 2007 | 162 | 2007 |
| Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells A Falanga, A Vignoli, M Marchetti, T Barbui Leukemia 17 (8), 1636-1642, 2003 | 144 | 2003 |
| Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia G Barosi, A Grossi, B Comotti, P Musto, G Gamba, M Marchetti British journal of haematology 114 (1), 78-83, 2001 | 141 | 2001 |
| Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines V Santini, PE Alessandrino, E Angelucci, G Barosi, A Billio, M Di Maio, ... Leukemia research 34 (12), 1576-1588, 2010 | 140 | 2010 |
| Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies G Barosi, M Elliott, L Canepa, F Ballerini, PP Piccaluga, G Visani, ... Leukemia & lymphoma 43 (12), 2301-2307, 2002 | 136 | 2002 |
